The effect of bumetanide on photodynamic therapy-induced peri-tumor edema of C6 glioma xenografts

Lasers Surg Med. 2014 Jul;46(5):422-30. doi: 10.1002/lsm.22248. Epub 2014 Apr 2.

Abstract

Objective: The aim of this study was to investigate the effect of bumetanide on peri-tumor edema caused by photodynamic therapy (PDT) of intraparenchymal C6 glioma xenografts.

Methods: Seven days after inoculation with C6 cells, rats with MRI-confirmed glioma received hematoporphyrin monomethyl ether (HMME)-mediated PDT, injection of bumetanide or a combination of the two treatments. After treatment, tumor volume, tumor weight, brain water content, microvessel density, expression of NKCC-1, Zonula occludens-1 (ZO-1), and animal survival time were examined.

Results: In the PDT group, tumor growth was significantly inhibited and survival prolonged. Bumetanide enhanced the efficacy of PDT and reduced PDT-induced peri-tumor edema in the combined PDT + bumetanide treatment group where NKCC-1 expression in response to PDT was significantly suppressed. ZO-1 expression was significantly suppressed in the PDT-only group. This suppression was not observed in the combined PDT + bumetanide treatment group.

Conclusion: PDT, in combination with bumetanide was seen to significantly inhibit the growth of C6 glioma, relieve peri-tumor edema caused by PDT alone and prolong survival. These results suggest that PDT, in combination with bumetanide, may be a useful and promising strategy in the treatment of human glioma.

Keywords: NKCC-1; Zonula occludens-1 (ZO-1); bumetanide; hematoporphyrin monomethyl ether; microvessel density; peri-tumor edema; photodynamic therapy.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Brain Neoplasms / drug therapy*
  • Bumetanide / therapeutic use*
  • Cell Line, Tumor
  • Diuretics / therapeutic use*
  • Edema / chemically induced
  • Edema / drug therapy*
  • Edema / metabolism
  • Glioma / drug therapy*
  • Hematoporphyrins / adverse effects
  • Hematoporphyrins / therapeutic use
  • Male
  • Photochemotherapy / adverse effects*
  • Photosensitizing Agents / adverse effects
  • Photosensitizing Agents / therapeutic use
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Transplantation, Heterologous
  • Treatment Outcome

Substances

  • Biomarkers
  • Diuretics
  • Hematoporphyrins
  • Photosensitizing Agents
  • hematoporphyrin monomethyl ether
  • Bumetanide